For laboratories wishing to accurately quantify Factor VIII activity, there is now a ready-to-use Chromogenic Factor VIII Assay. The CRYOcheck™ assay is designed for ease of use and to minimize ...
HALIFAX, NS, July 20, 2020 /CNW/ - Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce FDA 510(k) clearance and the launch of its new CRYOcheck ...
Precision BioLogic originally developed CRYOcheck Chromogenic Factor VIII in response to a growing demand for chromogenic assays 1. Launched in 2020, it was the first commercially available, ...
Hemophilia A and B are X-linked bleeding disorders characterized by partial or complete absence of clotting factors VIII and IX (FVIII and FIX, respectively). FVIII and FIX are critical coagulation ...
The phase 3 trial of valoctocogene roxaparvovec for severe hemophilia A showed it reduced bleeding events as well as the use of factor VIII concentrates. A phase 3 trial of valoctocogene roxaparvovec, ...
Sponsored by: Diagnostica Stago, Inc. In clinical laboratory settings, coagulation factor tests are routinely conducted to identify inherited or acquired deficiencies in patients suspected of an ...
With the emergence of extended half-life factor IX (FIX) replacement therapies, researchers and laboratorians have identified the growing importance of chromogenic assays along with one-stage clotting ...
HALIFAX, NS, Sept. 10, 2025 /CNW/ - Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the expanded utility of its CRYOcheck Chromogenic Factor VIII ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results